MXCT vs TMO
MXCT: MaxCyte provides proprietary non-viral cell engineering technology and gene-editing assessment services that empower developers to create next-generation cell and gene therapies. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | MXCT | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $1.47 | $694.02 | |
| Market cap | $152M | $256.6B | |
| P/E as of 2026-10-21 | n/a | 37.35 | |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | n/a | 179.97 | |
| Net margin FY2025, SEC XBRL | -135.1% | +15.0% | TMO higher |
| Gross margin FY2025, SEC XBRL | +81.2% | n/a | |
| Operating margin FY2025, SEC XBRL | -157.1% | +17.4% | TMO higher |
| ROE FY2025, SEC XBRL | -26.0% | +12.6% | TMO higher |
| ROA FY2025, SEC XBRL | -22.0% | +6.1% | TMO higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-27 | n/a | 0.87 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -14.5% | +3.9% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | -9.3% | -0.3% | TMO higher |
| Dividend yield as of 2026-09-02 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | TMO higher |
| Beta as of 2026-09-03 | 1.22 | 0.77 | |
| 1-year return as of 2026-10-21 close | -14.0% | +24.4% | TMO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.